| olanzapine / Generic mfg. |
NCT04535141: Olanzapine for Nausea/Vomiting Prophylaxis in Recipients of Hematopoietic Stem Cell Transplants |
|
|
| Completed | 3 | 91 | US | Olanzapine 5 MG, Zyprexa, Placebo | UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill | Chemotherapy-induced Nausea and Vomiting | 04/22 | 04/22 | | |
| Completed | 3 | 557 | RoW | Olanzapine+NK-1 RA+5-HT3 RA, Dexamethasone+NK-1 RA+5-HT3 RA, Acidocont, Deronil, Dexacortal, Desameton, Fluprednisolone, (11β，16α）-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione | Fifth Affiliated Hospital, Sun Yat-Sen University | Chemotherapy-induced Nausea and Vomiting | 05/22 | 07/22 | | |
ChiCTR2000031979: Exploration of intervention measures for olanzapine-related metabolic syndrome |
|
|
| Not yet recruiting | 3 | 90 | | Olanzapine plus berberine placebo ;Olanzapine plus berberine ;Piperone instead of olanzapine | Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Hui'ai Hospital); Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Hui'ai Hospital), 300000 | schizophrenia | | | | |
2021-005618-32: Dexamethasone, olanzapine, hemodynamics, and ventilation in cardiac surgery Dexamethason, olanzapin, hæmodynamik og ventilation til hjertekirurgi |
|
|
| Not yet recruiting | 3 | 1200 | Europe | Dexavit, Solution for injection, Tablet, Dexavit, Olanzapine | Rigshospitalet, Rigshospitalet | We investigate the efficacy of two pharmaceutical interventions for reducing mortality and organ damage, and shortening length of hospital stay in patients undergoing heart surgery (i.e. coronary artery bypass grafting and/or heart valve replacement)., Patients undergoing heart surgery are vulnerable to organ damage occurring during the operation. We investigate interventions to limit this damage., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
| Recruiting | 3 | 164 | RoW | Olanzapine 5 MG, Zyprexa, Placebo | Cairo University | Anorexia | 09/22 | 09/22 | | |
2022-001865-11: A Study to Test if TV-44749 is Effective in Relieving Schizophrenia |
|
|
| Not yet recruiting | 3 | 640 | Europe | Olanzapine, TV44749, Powder and solvent for prolonged-release suspension for injection | Teva Branded Pharmaceutical Products R&D, Inc., Teva Branded Pharmaceutical Products R&D, Inc. | Schizophrenia is a serious mental disorder in which people interpret reality abnormally. It is a severely debilitating psychotic disorder characterized by positive symptoms (eg, delusions, hallucinations, and grossly disorganized behavior) and negative symptoms (eg, affective flattening, alogia, and avolition)., Schizophrenia is a mental disorder that may result in some combination of hallucinations, delusions, and extremely disordered thinking and behavior that impairs daily functioning and can be disabling, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
NCT04833023: HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled Trial |
|
|
| Recruiting | 3 | 72 | RoW | Haldol 2mg/ml oral solution, Olanzapine Actavis 5mg orodispersible tablet | Tan Tock Seng Hospital | Haloperidol, Advanced Cancer, Hyperactive Delirium, Olanzapine, End-stage Organ Disease | 12/24 | 12/24 | | |
NCT05403580: Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer |
|
|
| Withdrawn | 3 | 20 | NA | Olanzapine, LY 170053, Zyprexa, Zyprexa Zydis, Placebo Administration, Questionnaire Administration | Mayo Clinic, National Cancer Institute (NCI) | Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm | 12/23 | 12/24 | | |
ACTRN12621001236886: PEAChY-O
Pharmacological Emergency management of Agitation in Children and Young people: a randomised controlled trial of Oral medication |
|
|
| Completed | 3 | 348 | | | Murdoch Children's Research Institute, Medical Research Futures Fund Million Minds Mission administered through the Department of Health, Western Australia Child Research Fund, Emergency Medicine Foundation | acute severe behavioural disturbance | | | | |
NCT06200168: Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer |
|
|
| Recruiting | 3 | 370 | RoW | Electroacupuncture, Standard antiemetic treatment, Sham electroacupuncture | Jiuda Zhao | Electroacupuncture, Olanzapine-contained Four-drug Antiemetic, Nausea and Vomiting | 10/26 | 12/26 | | |
ChiCTR2100049820: Efficacy and safety of olanzapine and dexmedetomidine in the treatment of ICU delirium |
|
|
| Not yet recruiting | 3 | 166 | | Oral olanzapine ;Intravenous dexmedetomidine | Dalian Municipal Central Hospital; Dalian Municipal Central Hospital, Open Project Program of Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders, Ministry of Education | Delirium | | | | |
NCT05244577: Olanzapine Combined With Fosaprepitant, Ondansetron, and Dexamethasone for Preventing Nausea and Vomiting in Patients With Testicular Cancer |
|
|
| Recruiting | 3 | 75 | RoW | Olanzapine Tablets, Olanzapine, Placebo | Shi Yanxia | Olanzapine, CINV, Testicular Cancer by AJCC V6 and V7 Stage, Cisplatin | 12/23 | 03/24 | | |
HELEN-009, NCT05242874: Fosaprepitant , Tropisetron and Olanzapine for the Prevention of Nausea and Vomiting in Patients With Breast Cancer |
|
|
| Completed | 3 | 442 | RoW | Fosaprepitant , Tropisetron and Olanzapine, Standard antiemetic therapy without dexamethasone, Fosaprepitant , Tropisetron, Dexamethasone and Olanzapine, Standard antiemetic therapy | Henan Cancer Hospital | Chemotherapy-induced Nausea and Vomiting | 08/23 | 08/23 | | |
NCT04503668: Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients |
|
|
| Terminated | 3 | 62 | US | Ondansetron, Dexamethasone, Neurokinin-1 Receptor Antagonist (NK1-RA), Fosaprepitant, Olanzapine, Zyprexa, Compazine | University of Michigan Rogel Cancer Center | Gynecologic Cancer | 01/24 | 03/24 | | |
OZONE-V, NCT05346731: Low Dose Olanzapine to the Prophylaxis of Nausea and Vomiting Induced by Chemotherapy in Children and Adolescents |
|
|
| Recruiting | 3 | 210 | RoW | Ondansetron, Dexamethasone, Aprepitant, Olanzapine | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Chemotherapy-induced Nausea and Vomiting | 03/24 | 08/24 | | |
NCT06314906: Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer |
|
|
| Recruiting | 3 | 370 | RoW | Electroacupuncture, Antiemetic Therapy, Sham electroacupuncture | Feixue Song | Electroacupuncture, Olanzapine-contained Four-drug Antiemetic, Nausea and Vomiting | 01/27 | 03/27 | | |
NCT05805800: Olanzapine and 5-HT3 With or Without Dexamethasone to Prevent CINV |
|
|
| Recruiting | 3 | 238 | RoW | 5HT3RA+Olanzapine, 5HT3RA+Olanzapine+Dexamethasone | Xingchen Peng | Chemotherapy-induced Nausea and Vomiting | 03/24 | 03/25 | | |
NCT06338683: Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer |
|
|
| Recruiting | 3 | 230 | RoW | Olanzapine 2.5 MG, Standard anti-tumor treatment, Nutritional advice | Qinghai Red Cross Hospital | Advanced Cancer, Olanzapine, Progression Free Survival | 03/27 | 03/28 | | |
NCT04939090: Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients |
|
|
| Recruiting | 3 | 360 | US | Olanzapine, Megestrol Acetate, Questionnaire Administration | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Advanced Malignant Solid Neoplasm, Anorexia, Hematopoietic and Lymphoid Cell Neoplasm | 05/26 | 12/26 | | |
NCT06200181: Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial |
|
|
| Recruiting | 3 | 87 | US | Olanzapine, Zypreza, Placebo | M.D. Anderson Cancer Center | Misuse, Opioid | 11/26 | 11/26 | | |
NCT06331520: NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens |
|
|
| Not yet recruiting | 3 | 627 | NA | Netupitant / Palonosetron Oral Capsule [Akynzeo], Olanzapine, Dexamethasone Oral | Fudan University | Chemotherapy-induced Nausea and Vomiting, Highly Emetogenic Chemotherapy | 05/25 | 05/26 | | |
NCT05669742: Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients |
|
|
| Not yet recruiting | 3 | 40 | NA | Empagliflozin, olanzapine | Tanta University | Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics | 06/24 | 12/24 | | |
NCT06482554: Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. |
|
|
| Recruiting | 3 | 80 | US | Lumateperone 42 mg, Lumateperone, Risperidone 2 mg, olanzapine; quetiapine; ziprasidone; aripiprazole | Louisiana State University Health Sciences Center Shreveport | Apathy, Schizophrenia, Schizophrenia; Psychosis | 12/26 | 12/26 | | |
SOLARIS, NCT05693935: A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia |
|
|
| Active, not recruiting | 3 | 675 | Europe, US, RoW | TV-44749 - Dose level 1, TV-44749 - Dose level 2, TV-44749 - Dose level 3, Placebo | Teva Branded Pharmaceutical Products R&D, Inc. | Schizophrenia | 03/24 | 01/25 | | |
NCT03367572: Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer |
|
|
| Completed | 3 | 1351 | US | Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Laboratory Biomarker Analysis, Netupitant/Palonosetron Hydrochloride, Akynzeo, Olanzapine, LY 170053, Zydis, Zyprexa, Zyprexa Zydis, Placebo, placebo therapy, PLCB, sham therapy, Prochlorperazine, RP 6140, SKF-4657, Quality-of-Life Assessment, Quality of Life Assessment | University of Rochester NCORP Research Base, National Cancer Institute (NCI) | Breast Carcinoma | 02/24 | 02/24 | | |
| Recruiting | 3 | 1000 | Europe | Dexamethasone, Dexavit, Backrest elevation, Early wakeup call, Olanzapine | Christian Hassager | Out-Of-Hospital Cardiac Arrest, Post-Cardiac Arrest Syndrome | 09/27 | 12/27 | | |
NCT00235352: Trial of Ampakine Added to Clozapine, Olanzapine or Risperidone in Patients With Schizophrenia |
|
|
| Completed | 2/3 | 105 | US | CX516 (Ampakine) | North Suffolk Mental Health Association, RespireRx | Schizophrenia | 04/05 | 02/07 | | |
| Withdrawn | 2/3 | 0 | US | Aripiprazole, Zyprexa, Risperdal | Washington University School of Medicine, Pfizer | Diabetes | 11/09 | 11/09 | | |
NCT00183404: Long-Term Olanzapine Treatment in Children With Autism |
|
|
| Completed | 2/3 | 32 | US | Olanzapine, Open Olanzapine | Drexel University, National Institute of Mental Health (NIMH) | Autism | 07/11 | 10/11 | | |
NCT00876772: Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS) |
|
|
| Completed | 2/3 | 40 | Europe | Olanzapine | Charite University, Berlin, Germany | Amyotrophic Lateral Sclerosis (ALS) | 07/12 | 07/12 | | |
| Terminated | 2/3 | 1210 | Japan, US, RoW | LY2140023, mGlu 2/3 Prodrug II, Olanzapine, Zyprexa, LY170053, Aripiprazole, Risperidone, Quetiapine | Eli Lilly and Company | Schizophrenia | 10/12 | 10/12 | | |
NCT03137121: Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients |
|
|
| Completed | 2/3 | 30 | US | Olanzapine, Zyprexa, Placebo | University of Alabama at Birmingham, Mayo Clinic | Advanced Cancer | 07/19 | 09/20 | | |
| Unknown status | 2/3 | 15 | Canada | Olanzapine 10 milligram, Bromocriptine 5 milligram, Placebo oral tablet | University Health Network, Toronto | Healthy | 01/20 | 06/20 | | |
NCT03631004: Pre-operative Olanzapine as Prophylactic Antiemetic in Oncologic Patients |
|
|
| Completed | 2/3 | 100 | RoW | Olanzapine, Treatment | Instituto do Cancer do Estado de São Paulo | Postoperative Nausea, Postoperative Nausea and Vomiting | 02/21 | 02/21 | | |
2020-006062-36: A Phase II/III, randomized, 4-week, placebo-controlled study, designed to determine the safety, tolerability, and efficacy of evenamide (NW-3509) in patients with chronic schizophrenia. |
|
|
| Ongoing | 2/3 | 196 | Europe, RoW | Evenamide, NW3509, Capsule, hard | Newron Pharmaceuticals S.p.A., NEWRON PHARMACEUTICALS SPA, Newron Pharmaceuticals S.p.A, Newron Pharmaceuticals S.p.A., Newron Pharmaceuticals S.p.A | Chronic schizophrenia, Chronic schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
